Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2022)

Gyre Therapeutics has reported Asset Writedowns and Impairment over the past 2 years, most recently at $200000.0 for Q1 2022.

Quarterly Asset Writedowns and Impairment changed N/A to $200000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Dec 2022, changed N/A year-over-year, with the annual reading at $200000.0 for FY2022, N/A changed from the prior year.
Asset Writedowns and Impairment was $200000.0 for Q1 2022 at Gyre Therapeutics, up from $134000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $200000.0 in Q1 2022 and troughed at $200000.0 in Q1 2022.